Numelvi Atinvicitinib Tablets for Dogs

NUMELVI (atinvicitinib tablets) is a prescription medication for the control of itch associated with allergic dermatitis in dogs. Numelvi starts working in as little as 2 to 4 hours¹* to relieve itch and deliver the comfort your dog deserves. Numelvi is given once daily with food at or around mealtime and is labeled for use in dogs and puppies 6 months of age and older.Discover NUMELVI™ (atinvicitinib tablets) for dogs. Available by prescription only. Proudly sourced directly from the manufacturer or their approved distributor. Guaranteed genuine and backed by the manufacturer.

How Its Sold

Sold as tablets in strengths of 4.8 mg, 7.2 mg, 21.6 mg or 31.6 mg in counts of 1, 30 or 90.

Special Precautions

NUMELVI is not for use in dogs less than 6 months of age or those with serious infections. NUMELVI may increase susceptibility to opportunistic infections, including demodicosis and interdigital furunculosis. Consider the risks and benefits of treatment prior to initiating NUMELVI in dogs with a history of recurrent demodicosis. NUMELVI is a JAK inhibitor. New neoplastic conditions (benign and malignant) have been reported in dogs treated with other JAK inhibitors. The effectiveness and safety of NUMELVI have not been evaluated in a field study beyond 28 days. The safe use of NUMELVI has not been evaluated in breeding, pregnant, or lactating dogs, nor in combination with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents. For complete safety information, refer to the product label.

Side Effects

ADVERSE REACTIONS:
In a masked field study assessing effectiveness and safety of Numelvi for the control of pruritus associated with allergic dermatitis in dogs, 144 Numelvi-treated dogs and 144 placebo-treated dogs were evaluated for safety for up to 28 days. Adverse reactions seen during the field study are summarized in Table 1 on the label.

Overdose Information

For technical information or to report a suspected adverse event, please contact Merck Animal Health at 1-800-224-5318 or https://www.merck-animal-health-usa.com. Safety Data Sheets (SDSs) can be found at https://www.merck.com/products/safety-data-sheets/#. For additional information about reporting adverse drug experiences for animal drugs, contact FDA at 1-888-FDA-VETS or https://www.fda.gov/reportanimalae.

Storage

Store at room temperature between 59-86°F

Active Ingredients

Atinvicitinib

References

*In a canine interleukin-31 (cIL-31)-induced pruritus model.
** No clinically relevant drug interactions observed during 28-day field trial in dogs with allergic dermatitis after use with antimicrobials (including topicals), ecto- and endoparasiticides (isoxazolines, milbemycins, avermectins, pyrethrins, and pyrethroids), analgesics, anesthetics, nutritional supplements, topical skin and ear cleansers that did not contain glucocorticoids, as well as medicated shampoos.
1. Kowalski T, Prohaczik A, Locke K, et al. The second-generation Janus kinase inhibitor atinvicitinib significantly reduces pruritus 2-4 hours after dosing dogs in a canine interleukin-31 model. Vet Dermatol. 2026;0:17-18. https://doi.org/10.1111/vde.70046
2. Data on File. Study Summary REF-11196. Merck Animal Health